Merck Acquires Verona Pharma for $10 Billion to Address Keytruda Patent Cliff

Merck's Strategic Acquisition of Verona Pharma

• 💰 Merck is acquiring Verona Pharma for approximately $10 billion to bolster its portfolio with an approved drug for Chronic Obstructive Pulmonary Disease (COPD).
• 🎯 This acquisition is a strategic move to mitigate the impact of the upcoming patent expiration for Merck's blockbuster cancer drug, Keytruda.

Addressing the Keytruda Patent Cliff

• ⚠️ Keytruda, Merck's top-selling drug, accounts for nearly half of the company's revenue and is set to lose patent protection later this decade.
• 📉 The projected loss of sales from Keytruda is estimated to be around $18 billion over the next five years.
• 🧩 Merck is adopting a "moneyball approach," acquiring multiple products like Verona's drug to collectively offset the revenue loss from Keytruda, rather than seeking a single replacement.

Verona's Ohtuvayre and the COPD Market

• 💨 Verona's drug, Ohtuvayre, recently received US approval for COPD, a respiratory disease that impedes airflow.
• 📈 Analysts predict Ohtuvayre could achieve peak sales of up to $4 billion, with the US COPD drug market projected to grow significantly.
• 🔬 Ohtuvayre is noted as the first novel inhaled mechanism for COPD in over two decades, and its launch has been described as one of the strongest in the market's history.

Merck's Dealmaking Strategy

• ⚖️ Merck has historically focused on deals in the $1 billion to $15 billion range, prioritizing promising science and approaches to diseases needing new therapies.
• 🚫 The company has avoided mega-mergers, believing they often lead to long-term inefficiencies and red tape.
• 🧩 This acquisition is seen as one of several components Merck is implementing to ensure a smoother revenue transition post-Keytruda exclusivity.

Patent Expirations and Biosimilars

• ⏳ Unlike pills, which can experience rapid sales drops after patent expiration, complex injectable medicines like Keytruda (biologics) face a less steep erosion curve due to the nature of biosimilars.
• 📊 It is anticipated that Keytruda's net price could decrease by about 50% five years after its patent expiration, a slower decline compared to traditional pills.